- Available:In stock936
- Availability date:2020-07-30
- Dosage form:Tablets
- In stock:936 Items
Atf-long is a preparation of a new class of substances, the molecule of which consists of adenosine-5′-triphosphate (atf), the amino acid histidine and salts of magnesium and potassium, and also has a pharmacological effect characteristic of it, which is absent in any of its other chemical components . atf-long stimulates energy metabolism, activity of cell membrane membrane transport systems, normalizes the concentration of potassium and magnesium ions, improves the antioxidant defense system of the myocardium, reduces the concentration of uric acid. atf-long has anti-ischemic, membrane-stabilizing, antiarrhythmic effect due to the normalization of metabolic processes in the myocardium with ischemia and hypoxia, improves central and peripheral hemodynamics, coronary circulation, increases myocardial contractility, functional state of the left ventricle and cardiac output, which leads to an improvement in physical indicators performance, reducing the frequency of attacks of angina pectoris and shortness of breath during physical exertion. the drug restores normal sinus rhythm in patients with paroxysmal supraventricular and supraventricular tachycardia, with atrial fibrillation and flutter, and also reduces the activity of ectopic foci (atrial and ventricular extrasystoles).
The drug is prescribed in complex treatment:
- IHD, unstable angina pectoris, angina pectoris of rest and tension;
- post-infarction and myocarditis cardiosclerosis (diffuse and focal cardiosclerosis);
- paroxysmal supraventricular and supraventricular tachycardia and other rhythm disturbances;
- vegetovascular dystonia;
- myocardial dystrophy;
- chronic fatigue syndrome;
- hyperuricemia of various origins;
- in order to increase tolerance to physical activity.
Atf-long tablets are taken sublingually and kept under the tongue until completely resorbed. single dose - 10–40 mg 3-4 times a day, regardless of food intake. the course of treatment is an average of 20-30 days (determined by the doctor). if necessary, the treatment is repeated after 10-15 days. the maximum daily dose is 160 mg.
- Hypersensitivity to the drug and its components; acute myocardial infarction; cardiogenic and other types of shock; obstructive diseases of the bronchopulmonary system; severe forms of ba; av blockade of the II – III degrees; hyperkalemia, hypermagnesemia; hemorrhagic stroke.
Possible: nausea, discomfort in the epigastrium, allergic reactions (including skin rash, itching, angioedema).
Also, a decrease in blood pressure, headache, tachycardia, increased diuresis, facial flushing, a feeling of heat, dizziness, discomfort in the chest, increased motility of the digestive canal, bronchospasm.
With prolonged and uncontrolled administration - hyperkalemia or hypermagnesemia.
Do not use:
- with a combination of AV blockade with other rhythm disturbances;
- with severe arterial hypotension;
- with cardiac glycosides due to an increased risk of AV blockade.
With prolonged use, it is necessary to control the level of potassium and magnesium in the blood. With caution prescribed with a tendency to bronchospasm.
It should be borne in mind that the tablets contain a small amount of sucrose and lactose, so the drug is not used in patients with rare hereditary forms of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome.
You should also limit the use of products containing caffeine (coffee, tea, drinks with cola).
Use during pregnancy and lactation. Use during pregnancy is contraindicated. Breastfeeding for the period of treatment should be discontinued.
Children. Not used for treatment in children.
The ability to influence the reaction rate when driving vehicles and working with mechanisms. If during treatment with the drug dizziness, a decrease in blood pressure are noted, you should refrain from driving vehicles and working with mechanisms.
Cardiac glycosides: increased risk of av blockade.
Potassium-sparing diuretics, potassium preparations, and ACE inhibitors: the risk of developing hyperkalemia is increased.
Magnerot and other magnesium preparations: hypermagnesemia.
Dipyridamole enhances the therapeutic effect of ATP-Long.
Xanthinol nicotinate, caffeine, theophylline, aminophylline: reduce the severity of the therapeutic effect of the drug ATP-Long.
ATP-Long can enhance the antianginal effect of β-adrenergic receptor blockers, calcium channel blockers, nitrates.
Perhaps the development of bradycardia, av-blockade and arterial hypotension, syncope.
Treatment. Stop taking the drug and start symptomatic therapy. With bradycardia, atropine sulfate is administered.
In a dry, dark place at a temperature of 3-5 ° C.